We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




Rectal Colonization by Klebsiella Leads to Different Risks for Bacteremia

By LabMedica International staff writers
Posted on 20 Jul 2021
Carbapenem-resistant Enterobacterales (CRE) represent a threat for public health, being among the top multidrug-resistant pathogens. More...
Intestinal colonization by CRE is a risk factor for developing subsequent infection.

In patients colonized by Klebsiella pneumoniae Carbapenemase (KPC)-producing Klebsiella pneumoniae (KPC-Kp), the rate of bloodstream infections (BSI) ranges from 8% to 23%, and specific factors for development of subsequent BSI have been identified. K.pneumoniae typically colonizes human mucosal surfaces of the oropharynx and gastrointestinal (GI) tract.

Infectious Disease specialists at the Pisan University Hospital (Pisa, Italy) and their colleagues carried out single-center, longitudinal, prospective, observational study involving consecutive adult patients with rectal colonization by CR-Kp admitted to the hospital from December 2018 to December 2019. After initial screening, all hospitalized patients were monitored through periodical rectal swabs on a regular basis (once a week in non-ICU and twice a week in ICU wards).

Rectal swabs were processed using three sequential steps: 1) molecular detection of bla genes involved in carbapenems resistance, 2) culture and pathogen identification, and 3) antibiotic susceptibility testing. Molecular screening was performed by the GeneXpert System Xpert-CARBA test (Cepheid, Sunnyvale, CA, USA). Species identification was performed using MALDI-TOF MS (Bruker Daltonics, Bremen, Germany). Antimicrobial susceptibility tests were performed with the SensiTitre system (Thermo Fisher Scientific, Waltham, MA, USA). Isolates were subjected to whole-genome sequencing (WGS) with an Illumina MiSeq platform (Illumina, San Diego, CA, USA). Rectal carriers were classified as: NDM, KPC, VIM and OXA-48.

The scientists reported that of 677 rectal carriers, 382/677 (56.4%) were colonized by NDM, 247/677 (36.5%) by KPC, 39/677 (5.8%) by VIM and 9/677 (1.3%) by OXA-48. Dissemination of NDM-KP was mostly sustained by ST147, while KPC-kp belonged to ST512. A higher rate of BSI was documented in NDM-compared to KPC-rectal carriers: 59/382, (15.4%) versus 20/247, (8.1%). Incidence rates of BSI/100 patients/month were significantly higher in the NDM (22.33) than in the KPC group (9.56). On multivariate analysis, multi-site extra-intestinal colonization, solid organ transplantation, invasive procedures, intravascular device, ICU, cephalosporin, fluoroquinolones and NDM rectal colonization (odds ratio [OR] = 3.27) were independently associated with BSI.

The authors concluded that their patients colonized by NDM-Kp are at higher risk of bacteremia compared to those colonized by KPC-Kp and the carbapenemase type is strongly related to the specific ST. Thus, the findings may reflect an increased virulence of the ST147 clone of Kp. The study was published on June 27, 2021 in the journal Clinical Microbiology and Infection.

Related Links:
Pisan University Hospital
Cepheid
Bruker Daltonics
Thermo Fisher Scientific
Illumina



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The method combines ultrasonic and fluorescence techniques to track amyloid aggregation in real time (Image Credit: Shutterstock)

Blood Test Measures Amyloid Seeding Activity to Detect Alzheimer’s Disease

Early, accurate diagnosis of Alzheimer’s disease (AD) remains challenging in routine practice, despite its role as the leading cause of dementia worldwide. Confirmation typically relies on cerebrospinal... Read more

Pathology

view channel
Image: TRUECAM automatically eliminates ambiguous or uninformative regions in whole-slide pathology images, enhancing the reliability of diagnostic analysis. (Photo courtesy of PolyU)

AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis

Ensuring reliable cancer diagnosis from digital pathology remains a critical challenge as clinical decisions rely on accurate slide interpretation. While artificial intelligence (AI) has accelerated whole-slide... Read more

Industry

view channel
Image: HealthTab will distribute the Abbott Afinion 2 Analyzer to NHS-linked pharmacies for hemoglobin A1c (HbA1c) and lipid profile testing. (Photo courtesy of Abbott)

New Collaboration Expands Point-of-Care Testing Across UK Community Pharmacies

HealthTab, a wholly owned subsidiary of Avricore Health, has entered a formal collaboration agreement with Abbott to supply and distribute Abbott’s point-of-care testing products in the UK through the... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.